Clinical Trial Update: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating B-cell depletion with rituximab for chronic fatigue syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue Syndrome
• Myalgic Encephalomyelitis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Status: COMPLETED